Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18)
Hyperthermische intraperitoneale Chemotherapie bei platinsensitivem rezidivierendem Ovarialkarzinom: randomisierte Studie zur Überlebensbewertung (HORSE; MITO-18)
Journal of Clinical Oncology · 2025-03 · 43 (7) · 852-860
DOI: 10.1200/jco.24.00686 ↗Auf einen Blick
Bei platinsensitivem rezidivierendem epithelialem Ovarialkarzinom erhöhte HIPEC zusätzlich zur sekundären zytoreduktiven Operation das progressionsfreie Überleben nicht. Das postoperative Nebenwirkungsprofil war ähnlich.
Fragestellung
Bringt HIPEC zusätzlich zur sekundären zytoreduktiven Operation ohne neoadjuvante Chemotherapie einen Vorteil beim progressionsfreien Überleben gegenüber der Operation allein?
Methode
Multizentrische randomisierte Phase-III-Studie; Randomisierung bei Resttumor ≤0,25 cm; postoperative platinhaltige Chemotherapie in beiden Gruppen.
Ergebnisse
167 randomisierte Patient:innen: 82 mit SCS plus HIPEC, 85 mit SCS allein. Medianes PFS 23 Monate (95 %-KI 17–29) vs. 25 Monate (95 %-KI 18–32). 5-Jahres-PRS 61,6 % vs. 75,9 %.
Schlussfolgerung der Autor:innen
Die Zugabe von HIPEC zur vollständigen oder nahezu vollständigen sekundären zytoreduktiven Operation brachte bei platinsensitiver peritonealer Rezidiverkrankung keinen PFS-Vorteil.
Kernaussagen
- PFS: 23 Monate mit SCS allein vs. 25 Monate mit SCS plus HIPEC
- 167 randomisierte Patient:innen in einer multizentrischen Phase-III-Studie
- Postoperative unerwünschte Ereignisse aller Schweregrade waren ähnlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025-03. Verfasst von Anna Fagotti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Ovarian Neoplasms, Cisplatin, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE To investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery (SCS) without neoadjuvant chemotherapy has a benefit on progression-free survival (PFS), as opposed to SCS alone in patients with platinum-sensitive recurrent epithelial ovarian cancer (platinum-free interval, >6 months). METHODS This was a multicenter randomized phase III study. Random assignment was performed at the time of surgery in cases with residual tumor ≤0.25 cm. HIPEC with cisplatin (CDDP) 75 mg/m 2 for 60 minutes at 41.5°C was administered at the end of surgery in the experimental arm. Both groups received postoperative platinum-based chemotherapy. The primary end point was PFS. The safety profile and postrecurrence survival (PRS) were the secondary end points. RESULTS A total of 167 patients underwent random assignment, 82 patients to SCS plus HIPEC (experimental arm) and 85 to SCS alone (control arm). The median follow-up was 83 months (IQR, 64-102). The median PFS was 23 months (95% CI, 17 to 29) in the group that underwent surgery alone and 25 months (95% CI, 18 to 32) in the group that underwent cytoreductive surgery with HIPEC. The probability of PRS at 5 years was 61.6% (95% CI, 50.8 to 72.4) in the SCS group and 75.9% (95% CI, 66.5 to 85.3) in the SCS plus HIPEC group. The incidence of postoperative adverse events of any grade was similar between the two groups. CONCLUSION The addition of HIPEC to complete or nearly complete primary SCS did not confer a benefit in terms of PFS in patients with platinum-sensitive peritoneal recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
- Università Cattolica del Sacro Cuore, Rome, Italy.
- UniCAMILLUS, International Medical University, Rome, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
- Department of Gynecologic Oncology, Università di Palermo, Palermo, Italy.
ORCID-Profile: Anna Fagotti, Barbara Costantini, Francesco Fanfani, Diana Giannarelli, Vito Chiantera, Giorgio Giorda, Giovanni Aletti, Vanda Salutari, Rita Trozzi, Giovanni Scambia
Zitieren
APA
Fagotti, A., Costantini, B., Fanfani, F., Giannarelli, D., De Iaco, P., Chiantera, V., Mandato, V., Giorda, G., Aletti, G., Greggi, S., Perrone, A. M., Salutari, V., Trozzi, R., & Scambia, G. (2025). Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18). Journal of Clinical Oncology, 43(7), 852-860. https://doi.org/10.1200/jco.24.00686
Vancouver
Fagotti A, Costantini B, Fanfani F, Giannarelli D, De Iaco P, Chiantera V, et al. Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18). Journal of Clinical Oncology. 2025;43(7):852-860. doi:10.1200/jco.24.00686
BibTeX
@article{Fagotti2025,
author = {Fagotti, Anna and Costantini, Barbara and Fanfani, Francesco and Giannarelli, Diana and De Iaco, Pierandrea and Chiantera, Vito and Mandato, Vincenzo and Giorda, Giorgio and Aletti, Giovanni and Greggi, Stefano and Perrone, A Myriam and Salutari, Vanda and Trozzi, Rita and Scambia, Giovanni},
title = {Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18)},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {7},
pages = {852--860},
doi = {10.1200/jco.24.00686}
}
EUVIMED